Press Releases

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth

ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

Saugeen Ojibway Nation, Bruce Power, Isogen and ITM advance initiative to double capacity of IPS to produce cancer-fighting medical isotopes

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

ITM Obtains Manufacturing License in the U.S.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board

ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics

ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225